AMENDMENTS TO THE CLAIMS

Claims 3, 8-12, 15, 18-23, 25-29, and 34 are currently pending. Please amend claims 3 and 15, as indicated below. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of Claims

1-2. (Canceled)

3. (Currently amended) A compound of the formula:



(Ie)

or



(Ig)

wherein:

Q_3 is a 5-6 membered aromatic carbocyclic or heterocyclic ring system; or an 8-10 membered bicyclic ring system ~~comprising~~ consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring; wherein Q_3 is substituted with 1 to 4 substituents, each of which is independently selected from halo; C_1-C_3 alkyl optionally substituted with NR'_2, OR', CO_2R' or $CONR'_2$; O-(C_1-C_3)-alkyl optionally substituted with NR'_2, OR', CO_2R' or $CONR'_2$; NR'_2; OCF_3; CF_3; NO_2; CO_2R'; CONHR'; SR'; $S(O_2)N(R')_2$; SCF_3; CN; $N(R')C(O)R^4$; $N(R')C(O)OR^4$; $N(R')C(O)C(O)R^4$; $N(R')S(O_2)R^4$; $N(R')R^4$; $N(R^4)_2$; OR^4; $OC(O)R^4$; $OP(O)_3H_2$; or $N=CH-N(R')_2$;

Q_2 is selected from 5-6 membered aromatic carbocyclic or heterocyclic ring systems, or 8-10 membered bicyclic ring systems consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring; wherein:

Q_2 is optionally substituted with up to 4 substituents, independently selected from halo, CH=N-OH, or CH=O; C_1-C_3 straight or branched alkyl optionally substituted with NR'_2, OR', CO_2R', $S(O_2)N(R')_2$, N=CH-$N(R')_2$, R^3, NH–CH_3, $NHCH_2CH_2OH$, $NHCH_2CH(OH)CH_2OH$, $CH_2OCH_2OCH_3$, $NHCH_2CH_2NH_2$, NH-phenyl, piperazinyl, pyrrolidinyl or $CONR'_2$; O-(C_1-C_3)-alkyl optionally substituted with NR'_2, OR', CO_2R', $S(O_2)N(R')_2$, N=CH-$N(R')_2$, R^3, or $CONR'_2$; NR'_2; OCF_3; CF_3; NO_2; CO_2R'; CONHR'; R^3; OR^3; NHR^3; SR^3; $C(O)R^3$; $C(O)N(R')R^3$; $C(O)OR^3$; SR'; $S(O_2)N(R')_2$; SCF_3; N=CH-$N(R')_2$; CH=N-OH; CH=O; or CN;

wherein R' is selected from hydrogen, (C_1-C_3)-alkyl; (C_2-C_3)-alkenyl or alkynyl; phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;

R^3 is selected from a 5-6 membered aromatic carbocyclic or heterocyclic ring system;

R^4 is (C_1-C_4)-alkyl optionally substituted with $N(R')_2$, OR', CO_2R', $CON(R')_2$, or $SO_2N(R^2)_2$; or a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with $N(R')_2$, OR', CO_2R', $CON(R')_2$, or $SO_2N(R^2)_2$;

X is selected from -S-, -O-, -$S(O_2)$-, -S(O)-, -$N(R^2)$-, -$N(R^2)$-$S(O_2)$-, -$N(R^2)$-C(O)O-, -O-C(O)-$N(R^2)$, -C(O)-, -C(O)O-, -O-C(O)-, -C(O)-$N(R^2)$-, -$N(R^2)$-C(O)-, -$C(R^2)_2$-, -$C(OR^2)_2$-, -CH(OH)-;

each R is independently selected from hydrogen, -R^2, -$N(R^2)_2$, -OR^2, SR^2, -C(O)-$N(R^2)_2$, -$S(O_2)$-$N(R^2)_2$, or -C(O)-OR^2, wherein two adjacent R are optionally bound to one another and, together with each carbon to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring;

R^2 is selected from hydrogen, (C_1-C_3)-alkyl, or (C_2-C_3)-alkenyl; each optionally substituted with -N(R')$_2$, -OR', SR', -C(O)-N(R')$_2$, -$S(O_2)$-N(R')$_2$, -C(O)-OR', or R^3;

Y is C;

A, if present, is CR'; and

n is 1;

provided that when a compound is of formula Ig, Q_3 is 2,6-dichlorophenyl and both R substituents are H, then Q_2 is neither phenyl nor p-fluorophenyl; and

when a compound is of formula Ie, and Q_3 is 2,6-dichlorophenyl, both R substituents are H, and X is S, then Q_2 is not phenyl.

4-7. (Canceled)

8. (Previously presented) The compound according to claim 3, wherein Q_2 is selected from phenyl or pyridyl and wherein Q_2 optionally contains up to 3 substituents, each of which is independently selected from chloro, fluoro, bromo, methyl, ethyl, isopropyl, -

OCH_3, -OH, $-NH_2$, $-CF_3$, $-OCF_3$, $-SCH_3$, $-OCH_3$, -C(O)OH, $-C(O)OCH_3$, $-CH_2NH_2$, $-N(CH_3)_2$, $-CH_2$-pyrrolidine and $-CH_2OH$.

9. (Previously presented) The compound according to claim 8, wherein, Q_2 is selected from:




CH3
F
Cl
CH3
CH
CH3
CH2CH3


F
CH3
CO2CH3
Cl
CH3
Br


F
CO2H
Cl
CO2H
Cl
CO2CH3
F
CO2CH3
Cl
NH2


NH2
N(CH3)2
Cl
NH2
Cl
N(CH3)2
F
N


Cl
N
F
NH2
F
N(CH3)2
Cl
OH
F
OH



















unsubstituted 2-pyridyl or unsubstituted phenyl.

10. (Previously presented) The compound according to claim 9, wherein Q_2 is selected from phenyl, 2-isopropylphenyl, 3,4-dimethylphenyl, 2-ethylphenyl, 3-fluorophenyl, 2-methylphenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 2-carbomethoxylphenyl, 2-carboxyphenyl, 2-methyl-4-chlorophenyl, 2-bromophenyl,

2-pyridyl, 2-methylenehydroxyphenyl, 4-fluorophenyl, 2-methyl-4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-difluorophenyl, 2-hydroxy-4-fluorophenyl or 2-methylenehydroxy-4-fluorophenyl.

11. (Previously presented) The compound according to claim 3, wherein X is selected from –S-, -O-, -$S(O_2)$-, -S(O)-, -$N(R^2)$-, -$C(R^2)_2$- or –C(O)-.

12. (Previously presented) The compound according to claim 11, wherein X is S.

13-14. (Canceled)

15. (Currently amended) The compound according to claim[[14]] 3, wherein each R attached to Y is independently selected from hydrogen or methyl.

16-17. (Canceled)

18. (Previously presented) The compound according to claim 3, wherein Q_3 is substituted with 2 to 4 substituents, wherein at least one of said substituents is present in the ortho position relative to the point of attachment of Q_3 to the rest of the inhibitor.

19. (Original) The compound according to claim 18, wherein both ortho positions are occupied by one of said independently selected substituents.

20. (Original) The compound according to claim 19, wherein Q_3 is a monocyclic carbocyclic ring; and each of said ortho substituents on Q_3 are independently selected from halo or methyl.

21. (Previously presented) The compound according to claim 19, wherein Q_3 contains 1 to 2 substituents in addition to said ortho substituents, said additional substituents being independently selected from NR'_2, OR', CO_2R' CN, $N(R')C(O)R^4$; $N(R')C(O)OR^4$; $N(R')C(O)C(O)R^4$; $N(R')S(O_2)R^4$; $N(R')R^4$; $N(R^4)_2$; OR^4; $OC(O)R^4$; $OP(O)_3H_2$; or N=CH-$N(R')_2$.

22. (Previously presented) The compound according to claim 3, wherein said compound is a compound of formula Ie:



and is selected from any one of the following compounds:

cpd #	Structure	cpd #	Structure
208		209	

23. (Previously presented) The compound according to claim 3, wherein said compound is a compound of formula Ig:



and is selected from any one of the following compounds:

cpd #	Structure	cpd #	Structure
302		310	

303		311	
304		312	
305		313	
306		314	

307		315	
308		316	
319		317	
320		318	
321		328	

322		329	
323		330	
324		331	
325		332	
326		333	

327		334	
337		335	
338		336	
339		346	
340		347	
341		348	

342		349	
343		350	
344		351	
345		352	

355		353	
356		354	
357		364	
358		365	

359		366	
360		367	
361		368	
362		369	

363		370	
373		371	
374		372	
375		382	

376		383	
377		385	
378		386	
379		387	

380		388	
381		389	
391		390	
392		396	

393		397	
394		398	
395		399	
		1301	

24. (Canceled)

25. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 3 effective to inhibit p38, and a pharmaceutically acceptable carrier.

26. (Previously presented) A method of treating inflammatory diseases, destructive bone disorders, reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, cardiac hypertrophy, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease in a patient, said method comprising administering to said patient a composition according to claim 25.

27. (Previously presented) The method according to claim 26, wherein said method is used to treat an inflammatory disease selected from acute pancreatitis, chronic pancreatitis, asthma, allergies, or adult respiratory distress syndrome.

28. (Previously presented) The method according to claim 26, wherein said method is used to treat rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease.

29. (Previously presented) The method according to claim 26, wherein said method is used to treat a destructive bone disorder selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder.

30-33. (Canceled)

34. (Previously presented) The method according to claim 26, wherein said method is used to treat ischemia/reperfusion in stroke, myocardial ischemia, or renal ischemia.

35-37. (Canceled)